chronic%20myeloid%20leukemia
CHRONIC MYELOID LEUKEMIA

Chronic myelogenous leukemia (CML) is a malignant myeloid disorder characterized by the presence of a distinctive cytogenetic abnormality known as the Philadelphia chromosome.

Exposure to ionizing radiation is the only known risk factor with median presentation at age >50 years old.

Three phases of the disorder are chronic, accelerated and blast.

Choice of therapy is influenced by age, availability of a donor, comorbidities and phase of CML.

Introduction

  • Also known as chronic myelogenous, myelocytic, or chronic granulocytic leukemia
  • Has three phases: chronic, accelerated & blast
  • Median age at presentation is at >50 years old

Definition

  • A myeloid disorder associated with Philadelphia (Ph) chromosome t(9;22)(q34;q11), a fusion of the breakpoint cluster region (BCR) & Abelson murine leukemia (ABL1) genes

Signs and Symptoms

  • Systemic symptoms:
    • Anemia
    • Abdominal fullness
    • Abdominal pain that may present with left upper quadrant pain & early satiety
    • Bleeding episodes due to platelet dysfunction
    • Fatigue
    • Malaise
    • Weight loss
  • Other frequent findings:
    • Splenomegaly
    • Platelet count raised
    • White blood cell (WBC) count increased
    • Involvement of lymph nodes, skin & soft tissue (patients with blast crisis)

Risk Factors

  • The only known risk factor is exposure to ionizing radiation
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
29 Nov 2017
Rapid onset opioids may allow for more effective treatment of breakthrough cancer pain as their pharmacokinetic profile closely mimics the pain’s time course
Christina Lau, 22 Oct 2015
A 21-gene expression assay can identify patients with early-stage breast cancer who can skip adjuvant chemotherapy without facing an increased risk of recurrence at 5 years.
Cathy Chow, PhD, 27 Aug 2015

HER2-positive breast cancer tends to be more aggressive, has worse patient prognosis, and responds less to treatment. A two-pronged approach to block the HER pathway via pertuzumab (Perjeta®, Roche), a first-in-class HER dimerization inhibitor, in combination with trastuzumab and chemotherapy, may offer more treatment options for HER2-positive metastatic breast cancer patients as well as those with early breast cancer. 

Saras Ramiya, 25 Oct 2017
The first patient-reported outcomes study on durvalumab treatment after chemoradiation in locally advanced non-small cell lung cancer (NSCLC) shows patients’ quality of life is similar to that of the patients who received placebo.